Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-08-09
2011-08-09
Tsang, Cecilia (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07994122
ABSTRACT:
The invention provides materials and methods for promoting weight loss or preventing weight gain in a subject. In particular, the invention provides novel glucagon analogue peptides effective in such methods and in the treatment of obesity, eating disorders, metabolic syndrome, and non-alcoholic liver steatosis. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
REFERENCES:
patent: 2005/0070469 (2005-03-01), Bloom et al.
patent: 0082731 (1983-06-01), None
patent: 2025684 (2009-02-01), None
patent: WO 98/11125 (1998-03-01), None
patent: WO 99/25727 (1999-05-01), None
patent: WO 99/46283 (1999-09-01), None
patent: WO 01/04156 (2001-01-01), None
patent: WO 03/022304 (2003-03-01), None
patent: WO 2004/062685 (2004-07-01), None
patent: WO 2006/134340 (2006-12-01), None
patent: WO 2007/024899 (2007-03-01), None
patent: WO 2008/101017 (2008-08-01), None
Authier et al., “Endosomal Proteolysis of Glucagon at Neutral pH Generates the Bioactive Degradation Product Miniglucagon-(19-29),”Endocrinology144: 5353-5364, 2003.
Blache et al., “Endopeptidase from Rat Liver Membranes, Which Generates Miniglucagon from Glucagon,”J. Biol. Chem. 268:21748-21753, 1993.
Cavanaugh et al., “Isolation and Structural Characterization of Proglucagon-Derived Peptides, Pancreatic Polypeptide, and Somatostatin from the UrodeleAmphiuma Tridactylum,” Gen. Compar. Endocrin. 101:12-20, 1996.
Dakin et al., “Oxyntomodulin Inhibits Food Intake in the Rat,”Endocrinology142:4244-4250, 2001.
England et al., “Glucagon Carboxyl-Terminal Derivatives: Preparation, Purification and Characterization,” Biochem. 21:940-950, 1982.
Frandsen et al., “Glucagon: Structure-Function Relationships Investigated by Sequence Deletions,”Hoppe-Seyler's Z. Physiol. Chem. 362:665-677, 1981.
Hjorth et al., “Glucagon and Glucagon-Like Peptide 1: Selective Receptor Recognition Via Distinct Peptide Epitopes,”J. Biol. Chem. 269:30121-30124, 1994.
Joshi et al., “The Estimation of Glutaminyl Deamidation and Aspartyl Cleavage Rates in Glucagon,”Int J. Pharma. 273:213-219, 2004.
Kallenbach et al., “Role of the Peptide Bond in Protein Structure and Folding,” inThe Amide Linkage, Chapter 18, pp. 599-619, 621, 622, 2000.
Zhu et al., “The Role of Dipeptidyl Peptidase IV in the Cleavage of Glucagon Family Peptides: In Vivo Metabolism of Pituitary Adenylate Cyclase Activating Polypeptide-(1-38),”J. Biol. Chem. 278:22418-22423, 2003.
NCBI Genbank Accession No. 721913A, downloaded Dec. 15, 2009.
Protest of U.S. Appl. No. 12/664,534 Pursuant to 37 C.F.R. § 1.291, mailed Jan. 13, 2010.
European Search Report from European Patent Application No. 07016032, completed Jan. 28, 2008.
International Search Report from PCT/GB2008/002041, completed Aug. 28, 2008, mailed Sep. 9, 2008.
International Preliminary Report on Patentability for PCT/GB2008/002041, issued Dec. 17, 2009.
Written Opinion of the International Searching Authority from PCT/GB2008/002041, completed Aug. 28, 2008, mailed Sep. 9, 2008.
Daugaard Jens Rosengren
Meier Eddi
Riber Ditte
Ryge Trine Skovlund
Bieker-Brady Kristina
Clark & Elbing LLP
Heard Thomas
Tsang Cecilia
Zealand Pharma A/S
LandOfFree
Glucagon analogues does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glucagon analogues, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glucagon analogues will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2629009